Repositioning Candidate Details
| Candidate ID: | R0948 |
| Source ID: | DB06225 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | HMR4011 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | HMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. IPL 576,092 has previously been investigated as a treatment for asthma. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in asthma. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | HMR4011 is a leukocyte suppressing/selective anti-inflammatory drug (LSAID) that was investigated for asthma treatment, a chronic inflammatory disease of the airways. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|